CN113845558A - 高效糖皮质激素 - Google Patents
高效糖皮质激素 Download PDFInfo
- Publication number
- CN113845558A CN113845558A CN202110799536.4A CN202110799536A CN113845558A CN 113845558 A CN113845558 A CN 113845558A CN 202110799536 A CN202110799536 A CN 202110799536A CN 113845558 A CN113845558 A CN 113845558A
- Authority
- CN
- China
- Prior art keywords
- compound
- group
- alkyl
- dex
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0036—Nitrogen-containing hetero ring
- C07J71/0042—Nitrogen only
- C07J71/0047—Nitrogen only at position 2(3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
- C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361882444P | 2013-09-25 | 2013-09-25 | |
| US61/882,444 | 2013-09-25 | ||
| CN201480063706.0A CN105744937A (zh) | 2013-09-25 | 2014-09-25 | 高效糖皮质激素 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480063706.0A Division CN105744937A (zh) | 2013-09-25 | 2014-09-25 | 高效糖皮质激素 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113845558A true CN113845558A (zh) | 2021-12-28 |
Family
ID=52744465
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110799536.4A Pending CN113845558A (zh) | 2013-09-25 | 2014-09-25 | 高效糖皮质激素 |
| CN201480063706.0A Pending CN105744937A (zh) | 2013-09-25 | 2014-09-25 | 高效糖皮质激素 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480063706.0A Pending CN105744937A (zh) | 2013-09-25 | 2014-09-25 | 高效糖皮质激素 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9975918B2 (https=) |
| EP (1) | EP3049089B1 (https=) |
| JP (1) | JP2016531852A (https=) |
| KR (1) | KR20160060688A (https=) |
| CN (2) | CN113845558A (https=) |
| AU (1) | AU2014324961A1 (https=) |
| ES (1) | ES2751457T3 (https=) |
| HK (1) | HK1222565A1 (https=) |
| WO (1) | WO2015048316A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025157225A1 (zh) * | 2024-01-24 | 2025-07-31 | 浙江柏拉阿图医药科技有限公司 | 一种高效力糖皮质激素化合物及其制备和用途 |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE071964T2 (hu) | 2015-07-06 | 2025-10-28 | Sage Therapeutics Inc | Oxiszterolok és alkalmazási eljárásaik |
| EP3828194B1 (en) | 2015-07-06 | 2025-04-16 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| SMT202200300T1 (it) | 2016-04-01 | 2022-09-14 | Sage Therapeutics Inc | Ossisteroli e relativi metodi d'uso |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| ES2935057T3 (es) | 2016-09-30 | 2023-03-01 | Sage Therapeutics Inc | C7 oxisteroles sustituidos y estos compuestos para su uso como moduladores de la NMDA |
| EP3525870B1 (en) * | 2016-10-14 | 2023-05-10 | Van Andel Research Institute | Highly potent glucocorticoids |
| KR20230051723A (ko) | 2016-10-18 | 2023-04-18 | 세이지 테라퓨틱스, 인크. | 옥시스테롤 및 그의 사용 방법 |
| RU2019115113A (ru) | 2016-10-18 | 2020-11-24 | Сейдж Терапьютикс, Инк. | Оксистеролы и способы их применения |
| CN115210229A (zh) | 2020-01-03 | 2022-10-18 | 博格有限责任公司 | 多环酰胺作为治疗癌症的ube2k调节剂 |
| CN117024499A (zh) * | 2023-07-17 | 2023-11-10 | 陕西汉江药业集团股份有限公司 | 在2位引入亚甲基羟基的甾体化合物制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102834406A (zh) * | 2009-06-16 | 2012-12-19 | 默沙东公司 | 作为糖皮质激素受体激动剂的新的[3.2-c]杂芳基甾体、其组合物和用途 |
| US20130237507A1 (en) * | 2009-04-03 | 2013-09-12 | Astrazeneca Ab, Intellectual Property | Novel Amide Compounds |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4049813A (en) | 1976-07-15 | 1977-09-20 | Sandoz, Inc. | Substituted isoxazolo pyridinones |
| WO2002102807A1 (en) | 2001-06-14 | 2002-12-27 | Banyu Pharmaceutical Co., Ltd. | Novel isoxazolopyridone derivatives and use thereof |
| GB0119911D0 (en) | 2001-08-15 | 2001-10-10 | Novartis Ag | Organic Compounds |
| EA201000436A1 (ru) | 2007-10-04 | 2010-10-29 | Астразенека Аб | Стероидные [3,2-с]пиразольные соединения, обладающие глюкокортикоидной активностью |
| CN102361640B (zh) | 2009-01-13 | 2016-10-19 | 范安德尔研究所 | 异噁唑吡啶酮在制备用于缓解或减轻温血哺乳动物关节炎和哮喘的症状的药物中的用途 |
| UY32523A (es) * | 2009-04-03 | 2010-10-29 | Astrazeneca Ab | Compuestos que tienen actividad agonista del receptor de glucocorticosteroides |
-
2014
- 2014-09-25 JP JP2016516578A patent/JP2016531852A/ja active Pending
- 2014-09-25 HK HK16110801.0A patent/HK1222565A1/zh unknown
- 2014-09-25 CN CN202110799536.4A patent/CN113845558A/zh active Pending
- 2014-09-25 ES ES14849674T patent/ES2751457T3/es active Active
- 2014-09-25 KR KR1020167010304A patent/KR20160060688A/ko not_active Withdrawn
- 2014-09-25 AU AU2014324961A patent/AU2014324961A1/en not_active Abandoned
- 2014-09-25 CN CN201480063706.0A patent/CN105744937A/zh active Pending
- 2014-09-25 WO PCT/US2014/057497 patent/WO2015048316A1/en not_active Ceased
- 2014-09-25 US US15/024,496 patent/US9975918B2/en active Active
- 2014-09-25 EP EP14849674.8A patent/EP3049089B1/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130237507A1 (en) * | 2009-04-03 | 2013-09-12 | Astrazeneca Ab, Intellectual Property | Novel Amide Compounds |
| CN102834406A (zh) * | 2009-06-16 | 2012-12-19 | 默沙东公司 | 作为糖皮质激素受体激动剂的新的[3.2-c]杂芳基甾体、其组合物和用途 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025157225A1 (zh) * | 2024-01-24 | 2025-07-31 | 浙江柏拉阿图医药科技有限公司 | 一种高效力糖皮质激素化合物及其制备和用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3049089B1 (en) | 2019-08-21 |
| HK1222565A1 (zh) | 2017-07-07 |
| EP3049089A4 (en) | 2017-08-09 |
| EP3049089A1 (en) | 2016-08-03 |
| US20160251393A1 (en) | 2016-09-01 |
| CN105744937A (zh) | 2016-07-06 |
| US9975918B2 (en) | 2018-05-22 |
| ES2751457T3 (es) | 2020-03-31 |
| JP2016531852A (ja) | 2016-10-13 |
| WO2015048316A1 (en) | 2015-04-02 |
| KR20160060688A (ko) | 2016-05-30 |
| AU2014324961A1 (en) | 2016-04-14 |
| AU2014324961A8 (en) | 2016-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113845558A (zh) | 高效糖皮质激素 | |
| CN101454005B (zh) | 用于治疗代谢性炎症介导的疾病的噻唑烷二酮类似物 | |
| CA3154608A1 (en) | Il-17a modulators and uses thereof | |
| EP3227295B1 (en) | 6,7-dihydropyrazolo[1,5- ]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglu2 receptors | |
| CN105308037B (zh) | 三唑化合物及其作为γ分泌酶调节剂的用途 | |
| JP2022132464A (ja) | 非常に強力な糖質コルチコイドの構造およびデザインのための機構 | |
| AU2012237028A1 (en) | Aureobasidin derivatives and methods of synthesis | |
| JP2014515741A5 (https=) | ||
| CN116970028A (zh) | 大环拟肽类蛋白酶抑制剂及其用途 | |
| HK40070300A (en) | Highly potent glucocorticoids | |
| TW201629025A (zh) | 化合物及其作為bace抑制劑之用途 | |
| CN107089955B (zh) | 磺酰胺类衍生物及其制备方法和用途 | |
| HK40017057A (en) | Structures and mechanism for the design of highly potent glucocorticoids | |
| HK40017057B (zh) | 用於设计高效力糖皮质激素的结构与机制 | |
| WO2025157225A1 (zh) | 一种高效力糖皮质激素化合物及其制备和用途 | |
| HK40128804A (zh) | 一种高效力糖皮质激素化合物及其制备和用途 | |
| HK40074980A (en) | Carboxylic acid aromatic amides as antagonists of bradykinin b1 receptor | |
| HK40074982A (en) | Carboxylic acid aromatic amides as antagonists of bradykinin b1 receptor | |
| HK1178066A (en) | Thiazolidinedione analogues | |
| HK1146484A1 (en) | Thiazolidinedione analogues for the treatment of hypertension | |
| HK1146484B (en) | Thiazolidinedione analogues for the treatment of hypertension | |
| HK1182099A (en) | Synthesis for thiazolidinedione compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40070300 Country of ref document: HK |
|
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20211228 |